Evaluation of the Novel Therapeutic Hepatitis B Virus Synthetic Long Peptide Vaccination ISA104

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2023
The goal of this clinical trial is to test ISA104 in patients with chronic hepatitis B. The main question\[s\] it aims to answer are: * How safe is ISA104? * Does ISA104 induce immunity against hepatitis B virus? Different doses of the vaccine ISA104 will be administered to participants. These participants are chronic HBV patients being actively treated with antiviral drugs. Researchers will compare the ISA104 vaccine to a placebo.
Epistemonikos ID: 8f82ea1c2e10d61c7ceeac1ecc575a49f9c7c19e
First added on: Feb 19, 2024